Cyteir Therapeutics, Inc. (CYT) Financial Statements (2024 and earlier)

Company Profile

Business Address 99 HAYDEN AVENUE
LEXINGTON, MA 02421
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) (USD)

9/30/2023
MRQ
12/31/2022
12/31/2021
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments147,120,000189,723,000
Cash and cash equivalents147,120,000189,723,000
Prepaid expense1,303,0001,767,000
Other undisclosed current assets786,0001,587,000
Total current assets:149,209,000193,077,000
Noncurrent Assets
Property, plant and equipment1,699,0002,055,000
Other noncurrent assets2,324,000256,000
Total noncurrent assets:4,023,0002,311,000
TOTAL ASSETS:153,232,000195,388,000
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities3,070,0004,063,000
Employee-related liabilities1,660,000
Accounts payable1,128,0001,785,000
Accrued liabilities1,942,000618,000
Other undisclosed current liabilities2,245,0003,448,000
Total current liabilities:5,315,0007,511,000
Noncurrent Liabilities
Liabilities, other than long-term debt1,631,000585,000
Deferred rent credit  384,000
Other liabilities1,631,000201,000
Total noncurrent liabilities:1,631,000585,000
Total liabilities:6,946,0008,096,000
Equity
Equity, attributable to parent146,286,000187,292,000
Common stock35,00035,000
Additional paid in capital284,365,000279,310,000
Accumulated deficit(138,114,000)(92,053,000)
Total equity:146,286,000187,292,000
TOTAL LIABILITIES AND EQUITY:153,232,000195,388,000

Income Statement (P&L) (USD)

9/30/2023
TTM
12/31/2022
12/31/2021
Operating expenses(48,170,000)(42,259,000)
Operating loss:(48,170,000)(42,259,000)
Nonoperating income2,109,000133,000
Investment income, nonoperating  
Other nonoperating income2,109,000133,000
Loss from continuing operations before equity method investments, income taxes:(46,061,000)(42,126,000)
Other undisclosed income (loss) from continuing operations before income taxes27,000(3,000)
Loss from continuing operations:(46,034,000)(42,129,000)
Loss before gain (loss) on sale of properties:(42,129,000)
Other undisclosed net income (loss)(27,000)3,000
Net loss available to common stockholders, diluted:(46,061,000)(42,126,000)

Comprehensive Income (USD)

9/30/2023
TTM
12/31/2022
12/31/2021
Net loss:(46,061,000)(42,126,000)
Comprehensive loss, net of tax, attributable to parent:(46,061,000)(42,126,000)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: